Latest analysis of lecanemab’s effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference

STOCKHOLM, July 19, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results of a detailed analysis of the Phase 3 Clarity AD study, presented at the Alzheimer’s Association International Conference (AAIC) 2023, demonstrated that…